合作客戶/
拜耳公司 |
同濟(jì)大學(xué) |
聯(lián)合大學(xué) |
美國保潔 |
美國強(qiáng)生 |
瑞士羅氏 |
相關(guān)新聞Info
-
> 低分子熱塑性樹脂體系CBT500/DBTL的界面張力與溫度的關(guān)聯(lián)性(一)
> ?表面張力和接觸角的關(guān)系(Young方程表達(dá)式)
> 不同濃度6∶2氟調(diào)磺酸的表面張力測定儀器及結(jié)果(二)
> 日本在地下存了5萬噸純凈水?
> 微納米顆粒三相泡沫體系的溶液特性、界面性能和驅(qū)油效果(一)
> 預(yù)測納米孔中油氣界面張力的狀態(tài)方程模型構(gòu)建
> 多相凝聚體系的界面張力計(jì)算方法及研究進(jìn)展
> 電子天平為什么必須預(yù)熱?超微量天平預(yù)熱時(shí)間
> 濃度、溫度、二價(jià)離子、礦化度等對無堿二元復(fù)合體系界面張力的影響
> 嗜熱鏈球菌發(fā)酵乳對全蛋液起泡性、pH、黏度、表面張力的影響(一)
推薦新聞Info
-
> 一種可降解、抑制泡沫再生的消泡劑制備方法和應(yīng)用
> 非-陰離子型醇醚磺酸鹽表面活性劑降低魏崗原油的表面張力(二)
> 非-陰離子型醇醚磺酸鹽表面活性劑降低魏崗原油的表面張力(一)
> 鈦基量子點(diǎn)納米復(fù)合高性能解水鎖劑制備及表面張力測定
> 如何有效避免釹鐵硼磁體擴(kuò)散源成分偏析
> 東辛原油酸性活性組分油水界面張力、動(dòng)態(tài)界面擴(kuò)張流變性質(zhì)研究(二)
> 東辛原油酸性活性組分油水界面張力、動(dòng)態(tài)界面擴(kuò)張流變性質(zhì)研究(一)
> 3種典型清水劑對不同原油組分界面穩(wěn)定性、油滴聚并行為的影響(二)
> 3種典型清水劑對不同原油組分界面穩(wěn)定性、油滴聚并行為的影響(一)
> 5μL樣品測表面張力?超微量天平如何破解納米材料研發(fā)困局
Delta-8 動(dòng)物胃腸道體內(nèi)中藥物的溶解度的測定——結(jié)論、工具書類!
來源:上海謂載 瀏覽 1533 次 發(fā)布時(shí)間:2021-11-26
結(jié)論
胃腸道pH值和緩沖容量的種間差異是重要的考慮因素,尤其是對胃腸道給藥的pHresponsive配方和可電離藥物。 因此,兔子和豬的空腸、回腸和近端結(jié)腸具有相對較高的緩沖容量,而豬遠(yuǎn)端結(jié)腸具有較低的緩沖容量是非常重要的考慮因素。 與人相比,大鼠、兔和豬的近端小腸和升結(jié)腸的液體的滲透壓和表面張力也較高。 胃腸道特征的這些差異導(dǎo)致潑尼松龍?jiān)诖笫篌w內(nèi)的溶解度較高(近端結(jié)腸除外),而潑尼松龍?jiān)谪i和兔體內(nèi)的溶解度與人類相當(dāng)。 因此,如果在大鼠的體液中測量,中性化合物潑尼松龍的溶解度可能被高估。 另一方面,可電離藥物美沙拉秦在兔和豬體內(nèi)的溶解度在小腸中部高于人,在結(jié)腸中低于人,僅在小腸遠(yuǎn)端與人相當(dāng)。 胃腸道環(huán)境的差異,如pH值、緩沖容量、滲透壓和表面張力,導(dǎo)致藥物溶解度的差異。 在兔子和豬中,美沙拉秦的溶解度在沿胃腸道向下移動(dòng)時(shí)發(fā)生顯著變化,這在很大程度上受管腔液的pH值和滲透壓的影響。
工具書類
1. Flaisher-Grinberg S et al. Models of mania: from facets to domains and from animal models to model animals. J Psychopharmacol 2010; 24: 437–438.
2. Insel TR. From animal models to model animals. Biol Psychiatry 2007; 62: 1337–1339.
3. Hannah-Poquette C et al. Modeling mania: further validation for Black Swiss mice as model animals. Behav Brain Res 2011; 223: 222–226.
4. Calabrese EJ. Gastrointestinal and dermal absorption – interspecies differences. Drug Metab Rev 1984; 15: 1013–1032.
5. Kararli TT. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory-animals. Biopharm Drug Dispos 1995; 16: 351–380.
6. McConnell EL et al. Measurements of rat and mouse gastrointestinal pH, fluid and lymphoid tissue, and implications for in-vivo experiments. J Pharm Pharmacol 2008; 60: 63–70.
7. Ward FW, Coates ME. Gastrointestinal pH measurement in rats: influence of the microbial flora, diet and fasting. Lab Anim 1987; 21: 216–222.
8. Smith HW. Observations on the Flora of the alimentary tract of animals and factors affecting its composition. J Pathol Bacteriol 1965; 89: 95–122.
9. Clarysse S et al. Postprandial evolution in composition and characteristics of human duodenal fluids in different nutritional states. J Pharm Sci 2009; 98: 1177–1192.
10. Kalantzi L et al. Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability/bioequivalence studies. Pharm Res 2006; 23: 165–176.
11. Fadda HM et al. Drug solubility in luminal fluids from different regions of the small and large intestine of humans. Mol Pharm 2010; 7: 1527– 1532.
12. Merchant HA et al. Assessment of gastrointestinal pH, fluid and lymphoid tissue in the guinea pig, rabbit and pig, and implications for their use in drug development. Eur J Pharm Sci 2011; 42: 3–10.
13. ToxNet. Mesalamine: Toxicology data network (ToxNet). US National Library of Medicine, CASRN: 89-57-6. 2014. (http://toxnet.nlm.nih.gov/cgi-bin/sis/ search2/r?dbs+hsdb:@term+@rn+@ rel+89-57-6, last accessed 25th June 2014).
14. Machatha SG, Yalkowsky SH. Comparison of the octanol/water partition coefficients calculated by ClogP, ACDlogP and KowWin to experimentally determined values. Int J Pharm 2005; 294: 185–192.
15. McConnell EL et al. Gut instincts: explorations in intestinal physiology and drug delivery. Int J Pharm 2008; 364: 213–226.
16. Mudie DM et al. Physiological parameters for oral delivery and in vitro testing. Mol Pharm 2010; 7: 1388– 1405.
17. French DL, Mauger JW. Evaluation of the physicochemical properties and dissolution characteristics of mesalamine: relevance to controlled intestinal drug delivery. Pharm Res 1993; 10: 1285–1290.
18. Perez de la Cruz Moreno M et al. Characterization of fasted-state human intestinal fluids collected from duodenum and jejunum. J Pharm Pharmacol 2006; 58: 1079–1089. 19. Diakidou A et al. Characterization of the contents of ascending colon to which drugs are exposed after oral administration to healthy adults. Pharm Res 2009; 26: 2141–2151.
Delta-8 動(dòng)物胃腸道體內(nèi)中藥物的溶解度的測定——摘要、介紹
Delta-8 動(dòng)物胃腸道體內(nèi)中藥物的溶解度的測定——材料和方法